4 results match your criteria: "University of Washington and Center for Health Studies[Affiliation]"
Minimizing bias in randomized trials: the importance of blinding.
JAMA
August 2010
Cardiovascular Health Research Unit, Department of Medicine, University of Washington and Center for Health Studies, Group Health, Seattle, WA 98101, USA.
Opportunities for enhancing the FDA guidance on pharmacovigilance.
JAMA
August 2008
Cardiovascular Health Research Unit, Department of Medicine, University of Washington and Center for Health Studies, Group Health, Seattle, WA 98101, USA.
Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation.
JAMA
April 2008
Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington and Center for Health Studies, Group Health, Seattle, WA 98101, USA.
Sponsors have a marketing interest to represent their products in the best light. This approach conflicts with scientific standards that require the symmetric and comparable reporting of safety and efficacy data. Selective reporting of the results of clinical trials can misrepresent the risk-benefit profile of drugs.
View Article and Find Full Text PDFA new era of cardiovascular disease epidemiology.
JAMA
November 2007
Cardiovascular Health Research Unit, Department of Medicine, University of Washington and Center for Health Studies, Group Health, Seattle, USA.